https://www.zacks.com/stock/news/2202226/merck-mrk-daiichi-sankyo-s-lung-cancer-adc-gets-priority-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202226
Dec 26, 2023 - Merck (MRK) and Daiichi Sankyo's regulatory filing for HER3-DXd gets the FDA's priority review grant for the treatment of adult patients with lung cancer. A final decision is expected on Jun 26, 2024.
zc:4561588943169413285
0
https://www.zacks.com/stock/news/2207963/why-investors-need-to-take-advantage-of-these-2-medical-stocks-now?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2207963
Jan 09, 2024 - Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
zc:-2592532621741874829
0
https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-ok-d-by-fda-for-expanded-cervical-cancer-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2210152
Jan 15, 2024 - FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
zc:5632938074738624243
0
https://www.zacks.com/commentary/2214056/q4-earnings-season-scorecard-and-fresh-analyst-reports-for-amazon-home-depot-merck?cid=CS-ZC-FT-research_daily-2214056
Jan 23, 2024 - Today's Research Daily features a real-time update on the Q4 earnings season and updated reports on Amazon (AMZN), Home Depot (HD), Merck (MRK) & others.
zc:-2227284028115583799
0
https://www.zacks.com/stock/news/2215849/merck-mrk-expected-to-beat-earnings-estimates-what-to-know-ahead-of-q4-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2215849
Jan 25, 2024 - Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zc:-146831527716827328
0
https://www.zacks.com/stock/news/2220214/pharma-stock-roundup-pfe-mrk-nvo-sny-s-q4-earnings-fda-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2220214
Feb 02, 2024 - Pfizer (PFE), Merck (MRK), Novartis (NVS), Novo Nordisk (NVO) and Sanofi (SNY) announce fourth-quarter and full-year 2023 results.
zc:4214353983792327271
0
https://www.zacks.com/stock/news/2240861/pfizer-pfe-gets-eu-nod-for-expanded-use-of-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240861
Mar 14, 2024 - Following the label expansion, Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine is authorized for use in individuals aged six weeks and older.
zc:-406310911123861384
0
https://www.zacks.com/stock/news/2243580/astrazeneca-azn-to-buy-fusion-pharmaceuticals-for-2-4b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243580
Mar 20, 2024 - AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.
zc:-4630128396138486577
0
https://www.zacks.com/stock/news/2245567/will-corcept-cort-bank-on-korlym-in-2024-amid-stiff-rivalry?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245567
Mar 25, 2024 - Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.
zc:-1327627035750226553
0
https://www.zacks.com/stock/news/2193811/exelixis-exel-collaborates-with-arcus-for-kidney-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193811
Dec 05, 2023 - Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.
zc:-1796747926215443315
0